In re: Generic Pharmaceuticals Pricing Antitrust Litigation, MDL No. 2724 (U.S. District Court for the Eastern District of Pennsylvania)

CGL is court-appointed Lead Counsel in this case against what “might be the biggest price-fixing scheme in U.S. history,” according to 60 Minutes / CBS News.  On behalf of a class of independent pharmacies and hospitals, CGL has filed cases against more than two dozen pharmaceutical companies that participated in an illegal system of market-splitting and coordinated price increases. This corporate collusion affected the prices of more than 200 generic drugs including Levothyroxine, Metoprolol, and Pravastatin. Independent pharmacies and hospitals lost millions of dollars as they were forced to pay illegally inflated prices to secure drugs for their patients and then dispensed those drugs at a loss.  

CGL began this case in 2017 and continues to gather evidence to prove the full scope of the overarching anticompetitive agreement. In court, CGL has repeatedly defeated the drug companies’ attempts to conceal evidence and to dismiss the case. In 2019, CGL’s independent investigation showed that several major drug distributors were members of the price-fixing ring.  

In this case, as in others, CGL coordinates with state Attorney General offices and with the Antitrust Division of the U.S. Department of Justice, which is pursuing parallel criminal cases against the drugmakers and their executives.

For additional information, please contact Peter Gil-Montllor at (202) 789-3960 or by email at